Part 3: NAFLD/NASH - Webcast: Liver Health - On-Demand Webcast - Driving Advances in Liver Health - Internal Medicine

Part 3: NAFLD/NASH (30 mins)

See the latest on NASH diagnosis and management, including noninvasive tests, monitoring for advanced fibrosis, and the future of treatment options.

Paul Y. Kwo, MD
Program Director

Manal F. Abdelmalek, MD, MPH

Oluwaseun Falade-Nwulia, MBBS, MPH

Physicians: maximum of 1.5 AMA PRA Category 1 Credits™

US Physicians: maximum of 1.5 Medical Knowledge MOC point(s)

Released: December 17, 2019 Expiration: December 16, 2020

Learning Objectives

Upon completion of this activity, participants should be able to:

Apply findings from successful programs implementing HCV diagnosis, linkage to care, and treatment strategies, resulting in an increased number of patients achieving key cascade of care targets

Identify appropriate candidates for HBV therapy and provide appropriate monitoring for individuals for whom treatment is not indicated

Critically appraise recent findings on NASH diagnosis and treatment to optimize current and future patient care

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director

Paul Y. Kwo, MD

Professor of Medicine
Director of Hepatology
Stanford University School of Medicine
Palo Alto, California

Paul K. Kwo, MD, has disclosed that he has received consulting fees from AbbVie, Conatus, Dova, EdiGene, Eisai, Ferring, Gilead Sciences, Quest, and Surrozen; has received funds for research support from Allergan, Assembly, Gilead Sciences, La Jolla, and HCV-TARGET Registries; and has ownership interest in Durect.

Faculty

Manal F. Abdelmalek, MD, MPH

Professor of Medicine
Division of Gastroenterology and Hepatology
Duke University
Durham, North Carolina

Manal F. Abdelmalek, MD, MPH, has disclosed that she has received consulting fees from Bristol-Myers Squibb, NGM Pharma, Prometic, and TaiwanJ; funds for research support from Allergan, Bristol-Myers Squibb, Galmed, Genfit, Gilead Sciences, Intercept, Madrigal, NGM Biopharma, Novartis, and TaiwanJ; and fees for non-CME/CE services from Genfit and Intercept.

Oluwaseun Falade-Nwulia, MBBS, MPH

Assistant Professor
Division of Infectious Diseases
Johns Hopkins University School of Medicine
Attending
Division of Infectious Diseases
Johns Hopkins Hospital
Baltimore, Maryland

Oluwaseun Falade-Nwulia, MBBS, MPH, has no relevant conflicts of interest to report.

Staff

Tiffany Hensley-McBain, PhD

Clinical Editor

Tiffany Hensley-McBain, PhD, has no relevant conflicts of interest to report.

Carolyn Skowronski, PharmD

Associate Director, Scientific Services

Carolyn Skowronski, PharmD, has no relevant conflicts of interest to report.

Jennifer Blanchette, PhD

Senior Scientific Director

Jennifer Blanchette, PhD, has no relevant conflicts of interest to report.

Jenny Schulz, PhD

Director, Scientific Services

Jenny Schulz, PhD, has no relevant conflicts of interest to report.

Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

The activities are intended for physicians and other healthcare providers who care for patients with or at risk of HBV, HCV, and/or NASH.

Goal

The goal of this activity is to improve the competence of learners to identify and manage patients with HBV, HCV, and/or NASH.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Learners must complete the post-test with a passing score of 75%. Physicians may follow the post test link provided at the end of the activity evaluation to claim ABIM MOC credit.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 17, 2019, through December 16, 2020:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 75% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.